{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T17:45:53Z","timestamp":1790790353950,"version":"4.1.0"},"reference-count":51,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,11,8]],"date-time":"2019-11-08T00:00:00Z","timestamp":1573171200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"DOI":"10.3389\/fendo.2019.00780","type":"journal-article","created":{"date-parts":[[2019,11,8]],"date-time":"2019-11-08T10:23:22Z","timestamp":1573208602000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":13,"title":["Insights Into GLP-1 and GIP Actions Emerging From Vildagliptin Mechanism Studies in Man"],"prefix":"10.3389","volume":"10","author":[{"given":"James E.","family":"Foley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2019,11,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1007\/s00125-016-3899-2","article-title":"Improved glucose regulation in type 2 diabetic patients with DPP-4 inhibitors: focus on alpha and beta cell function and lipid metabolism","volume":"59","author":"Ahr\u00e9n","year":"2016","journal-title":"Diabetologia."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1056\/NEJM199205143262003","article-title":"Antidiabetic effect of glucagon-like peptide-1 (7-36) amide in normal subjects and patients with diabetes mellitus","volume":"326","author":"Gutnaik","year":"1992","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"56","DOI":"10.17925\/EE.2017.13.02.56","article-title":"The vildagliptin experience \u2013 25 years since the initiation of the novartis glucagon-like peptide-1 based therapy programme and 10 years since the first vildagliptin registration","volume":"13","author":"Foley","year":"2017","journal-title":"Eur Endocrinol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1111\/j.1432-1033.1993.tb17986.x","article-title":"Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide glucagon-like peptide-1(7-36) amide peptide histidine methionine and is responsible for their degradation in human serum","volume":"214","author":"Mentlein","year":"1993","journal-title":"Eur J Biochem"},{"key":"B5","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1210\/jcem.80.3.7883856","article-title":"Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo","volume":"80","author":"Deacon","year":"1995","journal-title":"J Clin Endocrinol Metab"},{"key":"B6","doi-asserted-by":"publisher","first-page":"869","DOI":"10.2337\/diacare.25.5.869","article-title":"Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes","volume":"25","author":"Ahr\u00e9n","year":"2002","journal-title":"Diabetes Care"},{"key":"B7","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1111\/j.1463-1326.2011.01414.x","article-title":"Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans","volume":"13","author":"Ahr\u00e9n","year":"2011","journal-title":"Diabetes Obes Metab"},{"key":"B8","doi-asserted-by":"publisher","first-page":"2774","DOI":"10.1021\/jm030091l","article-title":"1-[[(3-hydroxy1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties","volume":"46","author":"Villhauer","year":"2003","journal-title":"J Med Chem"},{"key":"B9","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1210\/jc.2003-031907","article-title":"Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes","volume":"89","author":"Ahr\u00e9n","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1210\/jc.2006-1882","article-title":"The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single dose administration in type 2 diabetic patients","volume":"92","author":"Balas","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"B11","doi-asserted-by":"publisher","first-page":"376","DOI":"10.3389\/fendo.2019.00376","article-title":"DPP-4 inhibition and the path to clinical proof","volume":"19","author":"Ahr\u00e9n","year":"2019","journal-title":"Front Endocrinol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"68","DOI":"10.17925\/EE.2017.13.02.68","article-title":"Clinical safety and tolerability of vildagliptin \u2013 insights from randomised trials, observational studies and postmarketing surveillance","volume":"13","author":"Mathieu","year":"2017","journal-title":"Eur Endocrinol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"2874","DOI":"10.2337\/diacare.27.12.2874","article-title":"Twelve\u2013 and fifty-two\u2013week efficacy of the dipeptidyl peptidase iv inhibitor laf237 in metformin-treated patients with type 2 diabetes","volume":"27","author":"Ahren","year":"2004","journal-title":"Diabetes Care."},{"key":"B14","doi-asserted-by":"publisher","first-page":"2440","DOI":"10.2337\/db16-0107","article-title":"Quantification of the contribution of GLP-1 to mediating insulinotropic effects of DPP-4 inhibition with vildagliptin in healthy subjects and type 2-diabetic patients using exendin [9-39] as a GLP-1 receptor antagonist","volume":"65","author":"Nauck","year":"2016","journal-title":"Diabetes."},{"key":"B15","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/S2213-8587(15)00482-9","article-title":"The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions","volume":"4","author":"Nauck","year":"2016","journal-title":"Lancet Diabetes Endocrinol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"108","DOI":"10.2337\/dc07-1441","article-title":"The dipeptidylpeptidase-4 inhibitor vildagliptin improves \u03b2-cell function and insulin sensitivity in subjects with impaired fasting glucose","volume":"31","author":"Utzschneider","year":"2008","journal-title":"Diabetes Care"},{"key":"B17","doi-asserted-by":"publisher","first-page":"30","DOI":"10.2337\/dc07-1616","article-title":"Effects of the dipeptidyl peptidase-IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance","volume":"31","author":"Rosenstock","year":"2008","journal-title":"Diabetes Care"},{"key":"B18","doi-asserted-by":"publisher","first-page":"4165","DOI":"10.1210\/jc.2006-1932","article-title":"The dipeptidyl peptidase 4 inhibitor vildagliptin does not accentuate glibenclamide-induced hypoglycemia but reduces glucoseinducedglucagon-likepeptide1andgastricinhibitorypolypeptide secretion","volume":"92","author":"El-Ouaghlidi","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"B19","doi-asserted-by":"publisher","first-page":"4888","DOI":"10.1210\/jc.2004-2460","article-title":"Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed \u03b2-cell function in patients with type 2 diabetes","volume":"90","author":"Mari","year":"2005","journal-title":"J Clin Endocrinol Metab."},{"key":"B20","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1210\/jc.2007-1639","article-title":"Characterization of the influence of vildagliptin on model-assessed-cell function in patients with type 2 diabetes and mild hyperglycemia","volume":"93","author":"Mari","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1210\/jc.2008-2152","article-title":"Vildagliptin enhances islet responsiveness to both hyper- and hypoglycemia in patients with type 2 diabetes","volume":"94","author":"Ahr\u00e9n","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1111\/j.1463-1326.2008.00875.x","article-title":"Evidence that vildagliptin attenuates deterioration of glycaemic control during 2 year treatment of patients with type 2 diabetes and mild hyperglycaemia","volume":"10","author":"Scherbaum","year":"2008","journal-title":"Diabetes Obes Metab."},{"key":"B23","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1210\/jc.2007-1369","article-title":"Measurements of islet function and glucose metabolism with the dipeptidyl peptidase 4 inhibitor vildagliptin inpatients with type 2 diabetes","volume":"93","author":"Azuma","year":"2008","journal-title":"J Clin Endocrinol Metab."},{"key":"B24","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1111\/j.1463-1326.2007.00835.x","article-title":"Robust improvements in fasting and prandial measures of beta-cell function with vildagliptin in drug-naive patients: analysis of pooled vildagliptin monotherapy database","volume":"10","author":"Pratley","year":"2008","journal-title":"Diabetes Obes Metab."},{"key":"B25","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1210\/jc.2010-2178","article-title":"Inhibition of DPP-4 with vildagliptin improved insulin secretion in response to oral as well as \u201cisoglycemic\u201d intravenous glucose without numerically changing the incretin effect in patients with type 2 diabetes","volume":"96","author":"Vardarli","year":"2011","journal-title":"J Clin Endocrinol Metab."},{"key":"B26","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1210\/jc.2008-1135","article-title":"Treatment with the DPP-4 inhibitor vildagliptin improves fasting islet-cell function in subjects with type 2 diabetes","volume":"94","author":"D'Alessio","year":"2008","journal-title":"J Clin Endocrinol Metab."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1007\/s00125-011-2167-8","article-title":"Beta cell function following 1year vildagliptin or placebo treatment and after 12week washout in drug-naive patients with type 2 diabetes and mild hyperglycaemia: a randomised controlled trial","volume":"54","author":"Foley","year":"2011","journal-title":"Diabetologia."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1007\/s00125-013-2927-8","article-title":"Enhanced beta cell function and anti-inflammatory effect after chronic treatment with the dipeptidyl peptidase 4 inhibitor vildagliptin in an advanced age diet induced obesity mouse model","volume":"56","author":"Omar","year":"2013","journal-title":"Diabetologia."},{"key":"B29","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1177\/0091270006299137","article-title":"Pharmacodynamics of vildagliptin in patients with type 2 diabetes during OGTT","volume":"47","author":"He","year":"2007","journal-title":"J Clin Pharmacol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"730","DOI":"10.2337\/dc09-1867","article-title":"Changes in prandial glucagon levels after 2-year treatment with vildagliptin or glimepiride inpatients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy","volume":"33","author":"Ahr\u00e9n","year":"2010","journal-title":"Diabetes Care."},{"key":"B31","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1055\/s-2008-1078754","article-title":"Effect of vildagliptin on glucagon concentration during meals in patients with type 1 diabetes","volume":"40","author":"Foley","year":"2008","journal-title":"Horm Metab Res."},{"key":"B32","doi-asserted-by":"publisher","first-page":"3799","DOI":"10.1210\/jc.2012-2332","article-title":"Vildagliptin reduces glucagon during hyperglycemia and sustains glucagon counter regulation during hypoglycemia in type 1 diabetes","volume":"97","author":"Farngren","year":"2012","journal-title":"J Clin Endocrinol Metab."},{"key":"B33","doi-asserted-by":"publisher","first-page":"2263","DOI":"10.1007\/s00125-008-1149-y","article-title":"Glucagon-like peptide-1, but not glucose-dependent insulinotropic peptide, inhibits glucagon secretion via somatostatin (receptor subtype 2) in the perfused rat pancreas","volume":"51","author":"de Heer","year":"2008","journal-title":"Diabetologia."},{"key":"B34","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1111\/dom.12284","article-title":"Glucagon dynamics during hypoglycemia and food-re-challenge following treatment with vildagliptin in insulin-treated patients with type 2 diabetes","volume":"16","author":"Farngren","year":"2014","journal-title":"Diabetes Obes Metab."},{"key":"B35","doi-asserted-by":"publisher","first-page":"3103","DOI":"10.2337\/db11-0979","article-title":"Glucose-dependent insulinotropic polypeptide: a bifunctional glucose-dependent regulator of glucagon and insulin secretion in humans","volume":"60","author":"Christensen","year":"2011","journal-title":"Diabetes."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1038\/oby.2006.129","article-title":"GIP effect on basal and isoproterenol-stimulated rat adipocyte FFA release","volume":"14","author":"Getty-Kaushik","year":"2006","journal-title":"Obesity."},{"key":"B37","doi-asserted-by":"publisher","first-page":"E603","DOI":"10.1152\/ajpendo.1985.249.6.E603","article-title":"GIP increases insulin receptor affinity and cellular sensitivity in adipocytes","volume":"249","author":"Starich","year":"1985","journal-title":"Am J Physiol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1007\/s001250051560","article-title":"Enlarged subcutaneous abdominal adipocyte size, but not obesity itself, predicts type II diabetes independent of insulin resistance Diabetologia","volume":"43","author":"Weyer","year":"2000"},{"key":"B39","doi-asserted-by":"publisher","first-page":"E779","DOI":"10.1152\/ajpendo.90233.2008","article-title":"Incretin and islet hormonal responses to fat and protein ingestion in healthy men","volume":"295","author":"Carr","year":"2008","journal-title":"Am J Physiol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1503\/cmaj.1031414","article-title":"Oral antihyperglycemic therapy for type 2 diabetes mellitus","volume":"172","author":"Cheng","year":"2005","journal-title":"Can Med Assoc J."},{"key":"B41","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.2337\/db07-1828","article-title":"Pioglitazone decreases fasting and postprandial endogenous glucose production in proportion to decrease in hepatic triglyceride content","volume":"57","author":"Ravikumar","year":"2008","journal-title":"Diabetes."},{"key":"B42","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1111\/j.1463-1326.2010.01275.x","article-title":"Hepatic steatosis: a role for de novo lipogenesis and the transcription factor SREBP-1c","volume":"12","author":"Ferre","year":"2010","journal-title":"Diabetes Obes Metab."},{"key":"B43","doi-asserted-by":"publisher","first-page":"710","DOI":"10.2337\/diacare.24.4.710","article-title":"Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone","volume":"24","author":"Miyazaki","year":"2001","journal-title":"Diabetes Care."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1210\/jc.2014-3794","article-title":"Effect of vildagliptin on hepatic steatosis","volume":"100","author":"Macauley","year":"2015","journal-title":"J Clin Endocrinol Metab."},{"key":"B45","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1007\/s00125-006-0340-2","article-title":"Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes","volume":"49","author":"Matikainen","year":"2006","journal-title":"Diabetologia."},{"key":"B46","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1002\/cphy.c130024","article-title":"Energy metabolism in liver","volume":"4","author":"Rui","year":"2014","journal-title":"Comp Physiol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"661","DOI":"10.2147\/VHRM.S73608","article-title":"Changes in body weight after 24 weeks of vildagliptin therapy as a function of fasting glucose levels in patients with type 2 diabetes","volume":"10","author":"Bl\u00fcher","year":"2014","journal-title":"Vasc Health Risk Manage."},{"key":"B48","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1111\/j.1365-2265.2008.03235.x","article-title":"The effect of dipeptidyl peptidase-4 inhibition on gastric volume, satiation and enteroendocrine secretion in type 2 diabetes: a double-blind, placebo-controlled crossover study","volume":"69","author":"Vella","year":"2008","journal-title":"Clin Endocrinol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1210\/jc.2008-1400","article-title":"Dipeptidylpeptidase-IV inhibition augments postprandial lipid mobilization andoxidation in type 2 diabetic patients","volume":"94","author":"Boschmann","year":"2009","journal-title":"J Clin Endocrinol Metab."},{"key":"B50","doi-asserted-by":"publisher","first-page":"541","DOI":"10.2147\/VHRM.S10952","article-title":"Weight neutrality with the DPP-4 inhibitor, vildagliptin: mechanistic basis and clinical experience","volume":"6","author":"Foley","year":"2010","journal-title":"Vasc Health Risk Manage."},{"key":"B51","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1016\/S0140-6736(19)32131-2","article-title":"Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial","volume":"394","author":"Matthews","year":"2019","journal-title":"Lancet"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fendo.2019.00780\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,8]],"date-time":"2019-11-08T10:23:24Z","timestamp":1573208604000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fendo.2019.00780\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,8]]},"references-count":51,"alternative-id":["10.3389\/fendo.2019.00780"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2019.00780","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,8]]},"article-number":"780"}}